Abstract
Doping is defined as the administration or intentional use of substances external to the body, however they are introduced, or as measures taken by an athlete before or during a sporting event with the aim of artificially and illegally improving his sporting Performance [18]. Physical Performance is physiologically activated by means of the intense Stimulation of all or nearly all the organs or apparatuses of the human body. This is particularly true for the cardiocirculatory System. There is no activity which does not require the immediate Support of blood circulation, and so any substance capable of ergotropically modifying the physical Performance has to act by stimulating the cardiocirculatory system. Many of them are normal deposit-releasing chemical mediators of cardiovascular ergotropic Stimuli, that are usually synthesised and metabolised in the human body, but the majority are substances which are not present physiologically but can indirectly stimulate active cardiac and vessel receptors. In the first group, the Stimuli are physiologically similar to those which normally occur during training sessions designed to improve gradually the responses of neuromodellers and so their artificial introduction into the circulation differs from normal physiology only in terms of their sudden effect and the lack of preparation on the part of the body as a whole; the substances in the second group have a reflex action which is accompanied by the large number of side effects which are themselves toxic for the organism.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Antonaccio MJ (1980) Farmacologia clinica cardiovascolare. Martinucci Ed
Appleby M, Eischer M, Martin M (1994) Myocardial infarction, hyperkalemia and ventricular tachicardia in young male body builder. J Cardiol 44:171–174
Bruno M (1990) Gli steroidi anabolizzanti ed il loro abuso nella pratica sportiva Clin Ter 135:159–72
Celotti F, Negri-Cesi P (1992) Anabolic Steroids. J Steroid Biochem Mol Biol 43:469–11
Cheever K, House Ma (1992) Cardiovascular implication of anabolic Steroid abuse. J Cardiovasc Nurs 6:19–30
Di Biase G, Labriola E (1966) Le catecolamine e Papparato cardiovascolare. Patrou Ed
Ferenchick GS (1991) Anabolic/androgenic Steroid abusewith cardiomyopaty in atlet. Am J Med 92:562
Ferenchick GS (1991) Anabolic/andogenic Steroid abuse and thrombosis, is there a connection? Med Hypotheses 35:27
Haupt HA (1993) Anabolic Steroid and growth hormone. Am J Sport Med 21:468–74
Katz AM (1981) Fisiologia del cuore. Cortina Ed
Kennedy MC, Lawrence C (1993) Anabolic Steroid abuse and cardiac death. Med J Aust 158:346–8
Jensen LK (1994) Biviz Kninger oy dopingcontrol Ved lrug of anabolic Steroid. Vgeskr-Laeger 156:58723–3
Luke JL et al (1990) Sudden cardiac death during exercise in a weight-ligter using anabolic Steroids. J Forensic Sei 35:1441–7
Schimd P (1990) Der Einsatz von Beta-Rezeptors-Blockern in Leistungssport. Wien Med Wochenschr 140:184–8
Smith DA, Perry PJ (1992) The efficacy of ergonogenic agents in athletic competition. Ann Pharmacother 26:520–8
Thomson PD et al (1992) Left ventricular funetion is not impaired in weightlifters who use anabolic Steroids. J Am Coli Cardiol 9:278–82
Venerando A, Zeppilli P (1982) Cardiologia dello sport. Masson Ed
Vecchiet L, Calligaris A, Montanari G, Resina A (1990) Trattato di medicina dello sport applicata al calcio. Menarini Ed
Weider AA, Melchert RE (1993) Cardiotoxiceffects of cocaine and anabolic-androgenic Steroids in the athlete. J Pharmacol-Toxical Methods 29:61–8
Zeppilli. Cuore d’atleta. Master Pharma Ed
Zinzen E, Clariys JP, Vanderstappen D, Vandenberg YJ (1994) The influence of triazolam and flunitruzepam an isokinetic and isometri muscle Performance Ergonomics 37:69–77
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer-Verlag Italia
About this chapter
Cite this chapter
Montemartini, C., Iraghi, G. (1997). IOC Banned Drugs and their Effects on the Cardiovascular System. In: Pelliccia, A., Caselli, G., Bellotti, P. (eds) Advances in Sports Cardiology. Springer, Milano. https://doi.org/10.1007/978-88-470-2298-0_23
Download citation
DOI: https://doi.org/10.1007/978-88-470-2298-0_23
Publisher Name: Springer, Milano
Print ISBN: 978-3-540-75036-9
Online ISBN: 978-88-470-2298-0
eBook Packages: Springer Book Archive